复方吡拉西坦治疗248例增龄相关记忆障碍

Double blind trial on “choline+piracetam” in treatment of age-associated memory impairment in 248 cases

目的 :观察复方吡拉西坦对增龄相关记忆障碍的疗效。方法 :双盲法治疗 496例增龄相关记忆障碍 (AAMI) ,记忆商(MQ) <10 0 ,随机对半分为复方吡拉西坦组与对照组 ,均为每次 2粒胶囊 ,每粒 0 .4g,tid,疗程 2 mo。 436例以韦氏记忆量表(WMS)评定疗效 ,6 0例以光反应时间评定疗效。结果 :2 18例复方吡拉西坦治疗前与治疗后 MQ分别为 83.5 0± 15 .0 4及94.96± 16 .5 4,P<0 .0 1;2 18例对照组治疗前后分别为 81.0 5± 13.78及 86 .6 7± 16 .0 5 ,P<0 .0 1;复方吡拉西坦与对照组治疗后复查 WMS增值分别为 11.19± 12 .13及 5 .5 5± 8.78,P<0 .0 1;2组有效率分别为 5 7.80 %及 33.0 3% (P<0 .0 1) ;复方吡拉西坦 (n=30 )对红、绿光简单及选择反应时间的缩短差值均显著大于对照组 (n=30 )。本组未见显著不良反应。结论 :复方吡拉西坦可显著提高 AAMI的 MQ值 ,并缩短光反应时间 ,对记忆障碍有一定改善作用。

AIM: To observe the effect of “choline+piracetam” to treat age associated memory impairment (AAMI). METHODS: Double blind trials was performed in 496 cases of AAMI in the aged and preaged with MQ<100 (WMS). The dosage of “choline+piracetam” and placebo was all 2 capsules (0 4 g/cap) tid for 2 mo. The effect was evaluated with MQ (WMS, 436 cases) and light reaction time (60 cases). RESULTS: The mean value of MQ (WMS) before and after treatment was 83 50±15 04 and 94 96± 16 54 ( P <0 01) in 218 cases treated with “choline+piracetam” and 81 05±13 78 and 86 67±16 05 ( P <0 01) in 218 cases in placebo group respectively. There was significant difference of mean value of WMS increment between “choline+piracetam” 11 19±12 13 and placebo 5 55±8 78, ( P <0 01). The total effective rate of the “choline+piracetam” and placebo were 57 80% and 33 03% respectively ( P < 0 01). Significant decrement of simple and chose light (red and green) reaction time was observed between treatment and placebo group. No significant side effects were observed. CONCLUSION: “Choline+piracetam” may increase MQ, decrease light reaction time. It is effective to improve memory function in the elderly.